Bayer's Kidney Drug Just Went 5 for 5 in Phase III Trials

Over 32 months, patients on Kerendia showed a statistically significant and clinically meaningful improvement in eGFR slope compared to placebo. In plain English: their kidneys deteriorated more slowly. The drug was also well-tolerated, with a safety profile consistent with what doctors have seen in previous trials.

Bayer hasn't released the full dataset yet (that's coming at an upcoming scientific conference), but the topline results are encouraging enough that the company is already planning an FDA submission to expand Kerendia's label to include non-diabetic CKD.

How Kerendia Works (Without a Biochemistry Degree)

Finerenone is what's called a non-steroidal mineralocorticoid receptor antagonist. That's a mouthful, so here's the short version: your body has a hormone called aldosterone that, when overactive, causes inflammation and scarring in your kidneys and heart. Older drugs that block this hormone are steroid-based and come with messy side effects. Kerendia blocks the same pathway but does it more selectively, like using a scalpel instead of a sledgehammer.

This cleaner mechanism is a big reason the drug keeps posting wins across different patient populations, from diabetic CKD to heart failure to now non-diabetic kidney disease.

Why Bayer Desperately Needed This

Bayer isn't exactly having the best decade. The German pharma giant has been grinding through a painful restructuring that includes roughly 12,000 layoffs and a target of €2 to €2.3 billion in annual savings by 2026. Its blockbuster blood thinner Xarelto is facing steep sales declines as patents expire. The company needs new revenue engines, and it needs them fast.

Kerendia is one of the brightest spots in the portfolio. Sales jumped 67% in Q2 2025, and Bayer has publicly discussed more than €3 billion in peak sales potential for the drug. Expanding the label to non-diabetic CKD would dramatically widen the addressable patient population, potentially turning that peak sales target from aspirational to achievable.

The drug isn't fighting alone, either. Bayer's renal pipeline includes nurandociguat (an oral drug in Phase II for CKD) and a Phase II candidate for Alport syndrome, a rare genetic kidney disease. There's also an ongoing trial of finerenone in CKD patients with type 1 diabetes, which showed a 25% reduction in a key kidney damage marker back in November 2025.

The Nephrology Gold Rush

Bayer isn't the only company eyeing the kidney disease market. The global nephrology drug market sits at roughly $18 billion in 2025, with projections pushing it toward $24 to $29 billion by the early 2030s. SGLT2 inhibitors like Jardiance have already muscled their way into CKD treatment. The competition is heating up.

But Kerendia has a distinct advantage: it works through a completely different mechanism than SGLT2 inhibitors, which means doctors can potentially use both together. Instead of competing for the same slot on a prescription pad, these drugs could be complementary. That's a much friendlier competitive dynamic than a head-to-head showdown.

What Happens Next

Bayer will present the full FIND-CKD data at an upcoming medical conference, which will give analysts and physicians a deeper look at exactly how well the drug performed across subgroups. After that, expect an FDA submission for the expanded label.

If approved, Kerendia would become one of the few drugs available for non-diabetic CKD patients who currently have limited options beyond blood pressure management. For a disease that affects hundreds of millions globally, that's not just a win for Bayer's balance sheet. It's a genuine step forward for patients who've been waiting a long time for something better than "manage and hope."

Five Phase III wins, zero losses. The streak is real, and Bayer is betting the next chapter of its turnaround on keeping it alive.

The €2.3 Billion Bet That Hearing Aids Are the Next Big Thing in MedTech

Amplifon just dropped €2.3 billion to buy the company that makes the hearing aids it sells, creating a vertically integrated giant in one of medtech's fastest-growing markets. The deal reshapes an entire industry, and the competition should be worried.